Aquestive Therapeutics Inc (AQST) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aquestive Therapeutics Inc stock (AQST) is currently trading at $3.88. Aquestive Therapeutics Inc PS ratio (Price-to-Sales) is 10.90. Analyst consensus price target for AQST is $8.89. WallStSmart rates AQST as Sell.
- AQST PE ratio analysis and historical PE chart
- AQST PS ratio (Price-to-Sales) history and trend
- AQST intrinsic value — DCF, Graham Number, EPV models
- AQST stock price prediction 2025 2026 2027 2028 2029 2030
- AQST fair value vs current price
- AQST insider transactions and insider buying
- Is AQST undervalued or overvalued?
- Aquestive Therapeutics Inc financial analysis — revenue, earnings, cash flow
- AQST Piotroski F-Score and Altman Z-Score
- AQST analyst price target and Smart Rating
Aquestive Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Aquestive Therapeutics Inc (AQST) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around operating margin and price/sales. Significant fundamental concerns warrant caution or avoidance.
Aquestive Therapeutics Inc (AQST) Key Strengths (1)
62.10% held by institutions, strong professional interest
Supporting Valuation Data
Aquestive Therapeutics Inc (AQST) Areas to Watch (5)
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 10.9x annual revenue
Modest revenue growth at 9.70%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Aquestive Therapeutics Inc (AQST) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Operating Margin, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (10.90) suggest expensive pricing. Growth concerns include Revenue Growth at 9.70%, which may limit upside. Profitability pressure is visible in Operating Margin at -221.60%, Profit Margin at -188.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -221.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AQST Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AQST's Price-to-Sales ratio of 10.90x trades at a 17% premium to its historical average of 9.35x (61th percentile). The current valuation is 67% below its historical high of 32.84x set in Aug 2018, and 512% above its historical low of 1.78x in Jun 2022. Over the past 12 months, the PS ratio has expanded from ~6.4x, reflecting growing market expectations outpacing revenue growth.
Compare AQST with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Aquestive Therapeutics Inc (AQST) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Aquestive Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 45M with 10% growth year-over-year. The company is currently unprofitable, posting a -188.1% profit margin.
Key Findings
The company is unprofitable with a -188.1% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.59, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Aquestive Therapeutics Inc.
Bottom Line
Aquestive Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aquestive Therapeutics Inc(AQST)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.